title: Silencing USP22 by asymmetric structure of interfering RNA inhibits proliferation and induces cell cycle arrest in bladder cancer cells.
abstract: The ubiquitin specific peptidase 22 (USP22) is a positive regulator of the growth of tumors. However, little is known about the impact of USP22 knockdown on the growth of human bladder cells. In the present study, we designed a series of asymmetric interfering RNAs (aiRNAs) and compared the efficacy of aiRNA and conventional symmetric interfering RNA (siRNA) in the silencing of USP22 expression and the growth of human bladder EJ cells in vitro and in vivo. In comparison with transfection with the USP22-specific siRNA, transfection with 15/21 aiRNA was more potent in down-regulating the USP22 expression and inhibiting EJ cell proliferation in vitro. Furthermore, transfection with 15/21 aiRNA induced higher frequency of EJ cells arrested at the G0/G1 phases, but did not trigger EJ cell apoptosis. Moreover, transfection with either the siRNA or 15/21 aiRNA up-regulated the expression of p53 and p21, but down-regulated the expression of cyclin E and Mdm2 in EJ cells. The up-regulated p53 expression induced by the specific siRNA or aiRNA was abrogated by induction of Mdm2 over-expression. In addition, treatment with the specific siRNA or aiRNA inhibited the growth of implanted human bladder tumors in mice and the aiRNA had more potent anti-tumor activity in vivo. Therefore, our data suggest that knockdown of USP22 expression by the aiRNA may down-regulate the expression of Mdm2 and cyclin E, resulting in the up-regulated expression of p53 and p21 and leading to cell cycling arrest and inhibition of human bladder EJ cell proliferation. Our findings indicate that the USP22-specific aiRNA may be a novel approach for the intervention of human bladder tumors.
authors.affiliation: Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1277 Jiefangda Road, Wuhan, 430022, People's Republic of China.
authors.forename: Lei
authors.initials: L
authors.lastname: Lv
authors.forename: Xing-Yuan
authors.initials: XY
authors.lastname: Xiao
authors.forename: Zhao-Hui
authors.initials: ZH
authors.lastname: Gu
authors.forename: Fu-Qing
authors.initials: FQ
authors.lastname: Zeng
authors.forename: Lu-Qi
authors.initials: LQ
authors.lastname: Huang
authors.forename: Guo-Song
authors.initials: GS
authors.lastname: Jiang
mesh_terms: D000818:Animals; D017209:Apoptosis; D001483:Base Sequence; D045744:Cell Line, Tumor; D017931:DNA Primers; D020868:Gene Silencing; D006801:Humans; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D016133:Polymerase Chain Reaction; D034622:RNA Interference; D034741:RNA, Small Interfering / Q000235:genetics; D013869:Thiolester Hydrolases / Q000235:genetics*; D043222:Ubiquitin Thiolesterase; D001749:Urinary Bladder Neoplasms / Q000235:genetics / Q000473:pathology*
chemical_list: D017931:DNA Primers; D034741:RNA, Small Interfering; D013869:Thiolester Hydrolases; D043222:Ubiquitin Thiolesterase; C527170:Usp22 protein, human
references.citation: Annu Rev Genet. 2005;39:537-59
references.pmid: 16285871
references.citation: Cancer Metastasis Rev. 2009 Dec;28(3-4):355-67
references.pmid: 19997963
references.citation: Gene Expr Patterns. 2006 Mar;6(3):277-84
references.pmid: 16378762
references.citation: J Clin Invest. 2005 Jun;115(6):1503-21
references.pmid: 15931389
references.citation: Eur Urol. 2006 Feb;49(2):226-34
references.pmid: 16413099
references.citation: Mol Cell. 2005 Dec 22;20(6):845-54
references.pmid: 16359901
references.citation: EMBO J. 2007 Feb 21;26(4):976-86
references.pmid: 17290220
references.citation: Nature. 2002 Jul 11;418(6894):244-51
references.pmid: 12110901
references.citation: Nature. 2007 Oct 25;449(7165):1068-72
references.pmid: 17914355
references.citation: Cell Cycle. 2008 Jun 1;7(11):1522-4
references.pmid: 18469533
references.citation: J Neurosci Methods. 2009 Feb 15;177(1):122-30
references.pmid: 18996411
references.citation: Proc Natl Acad Sci U S A. 2008 Feb 19;105(7):2415-20
references.pmid: 18272492
references.citation: Nature. 2000 Nov 16;408(6810):307-10
references.pmid: 11099028
references.citation: Cell Cycle. 2007 May 2;6(9):1077-89
references.pmid: 17404514
references.citation: Nucleic Acids Res. 2008 Oct;36(18):5812-21
references.pmid: 18782830
references.citation: Cancer Lett. 2009 Jan 8;273(1):164-71
references.pmid: 18793823
references.citation: Mol Ther. 2009 Apr;17(4):725-32
references.pmid: 19156133
references.citation: Mol Cell Biol. 2005 Feb;25(3):1173-82
references.pmid: 15657442
references.citation: Biochem Biophys Res Commun. 2007 Aug 10;359(4):997-1003
references.pmid: 17577577
references.citation: J Immunol Methods. 2009 Oct 31;350(1-2):29-35
references.pmid: 19647746
references.citation: Eur J Cancer Prev. 2005 Aug;14(4):329-35
references.pmid: 16030422
references.citation: Oncogene. 2010 Mar 4;29(9):1270-9
references.pmid: 19946331
references.citation: Urology. 2010 Feb;75(2):334-9
references.pmid: 19963252
references.citation: Mol Cell. 2004 Mar 26;13(6):879-86
references.pmid: 15053880
references.citation: Nat Rev Cancer. 2005 Sep;5(9):713-25
references.pmid: 16110317
references.citation: Mol Cancer Res. 2003 Dec;1(14):1001-8
references.pmid: 14707283
references.citation: Mol Cell. 2008 Jan 18;29(1):102-11
references.pmid: 18206973
references.citation: Cell Cycle. 2005 Sep;4(9):1171-5
references.pmid: 16082216
references.citation: Mol Cell. 2008 Oct 24;32(2):180-9
references.pmid: 18951086
references.citation: Can Urol Assoc J. 2008 Jun;2(3):212-21
references.pmid: 18682775
references.citation: Nat Biotechnol. 2008 Dec;26(12):1379-82
references.pmid: 19029911